Abstract: A method of treating a myeloid neoplasm in a subject, the method comprising administering to a subject in need thereof a 50 to 500 ?g dose of a pegylated interferon-? once every 2 to 8 weeks, the pegylated interferon-? being a conjugate of formula I: in which each of R1, R2, R3, R4, and R5, independently, is H, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, aryl, heteraryl, C3-8 cycloalkyl, or C3-8 heterocycloalkyl; each of A1 and A2, independently, is a polymer moiety; each of G1, G2, and G3, independently, is a bond or a linking functional group; P is an interferon-? moiety; m is 0 or an integer of 1-10; and n is an integer of 1-10; wherein the subject has a complete molecular response, the complete molecular response including a JAK2617F allele burden below 1%.

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of myeloproliferative disorders in patients presenting a dysregulation of the JAK2-STAT signalling pathway. Using MPN mouse model and clonogenic methyl-cellulose cultures of patient progenitors, the inventors demonstrate that combining ARS with IFN improves most of the benefits provided by IFN alone during MPN treatment. In particular, the present invention relates to a method of treating a myeloproliferative disorder in a patient presenting a dysregulation of the JAK2-STAT signalling pathway comprising administering to the patient a therapeutically effective combination of an interferon polypeptide and an arsenic compound.